Raymond James Reiterates Strong Buy Rating on ARS Pharmaceuticals Inc (SPRY)

March 2, 2026 6:37 AM EST Send to a Friend
Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $34.00 price target on ARS Pharmaceuticals Inc (NASDAQ: SPRY).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login